transplant rejection CareDx Q2 Revenues Grow 9 Percent but Miss Estimates as Firm Lowers Full-Year Guidance Revenues rose 9 percent on test service growth, as the company’s net loss swelled to $21.7 million from $1.9 million in Q2 of last year. GenDx Licenses cfDNA Assay for Rejection Monitoring From Medical College of Wisconsin The method allows for less invasive and more economical post-transplant monitoring and could also be adapted for other organ applications. CareDx Receives CE Mark for Hematopoietic Cell Transplantation Testing Kit, Analysis Software The designation furthers the firm's expansion into the stem cell transplant space, which began with the launch of AlloCell in 2020. CareDx Q1 Revenues up 18 Percent The firm said March was its highest ever month of testing volume for its heart and kidney transplant testing services. Natera Adds Clinical Utility Evidence for Cell-Free DNA in Allograft Health Premium Three new studies focusing on the heart, lungs, and kidneys add to a growing body of evidence in support of donor-derived cell-free DNA as an organ health measure. Feb 25, 2022 Thermo Fisher Scientific Deal Expands Possibilities for Exosome Dx Business, Bio-Techne CEO Says Premium Feb 22, 2022 Bio-Techne, Thermo Fisher Scientific to Further Develop, Commercialize Kidney Transplant Rejection Assay Feb 2, 2022 Cell-Free DNA Assay Shows Promise for Detecting Stem Cell Transplant Complications Premium Dec 23, 2021 Oncocyte Switches Gears on Transplant Test Commercialization, Plans to Launch LDT Next Year Premium Dec 13, 2021 CareDx to Study AlloSure Kidney for Routine Organ Transplant Surveillance in Pediatric Patients Nov 5, 2021 Natera Aiming to Translate Success in Colorectal Cancer Diagnostics Into Other Areas Premium Oct 29, 2021 CareDx Works Toward Goal of Becoming Essential Transplant Diagnostics Company Premium Sep 29, 2021 CareDx Patents Deemed Invalid in Court Battle Against Natera, Eurofins Viracor Aug 11, 2021 Oncocyte Updates Plans for Chronix Transplant Tech; Will Develop and Market Kits in Europe Premium May 6, 2021 Natera Q1 Revenues Grow 62 Percent May 5, 2021 CareDx Q1 Revenues up 76 Percent Apr 28, 2021 NY State Department of Health Approves Eurofins Viracor Transplant Rejection Tests Mar 19, 2021 NephroSant Readies Launch of Kidney Transplant Rejection Assay Premium Mar 17, 2021 CareDx Acquires European Transplant Surveillance Software Firm BFS Molecular Mar 16, 2021 NephroSant Raises $16M in Series A Funding Round Feb 26, 2021 GenDx HLA Genotyping Products Receives Health Canada IVD Approval Feb 25, 2021 CareDx Expanding Diagnostic Tech Into Cell Transplant Monitoring Premium Feb 24, 2021 CareDx Q4 Revenues Up 64 Percent Feb 8, 2021 Eurofins Viracor, Cleveland Clinic Sign License Deal for Kidney Transplant Rejection Biomarker Test Feb 2, 2021 Devyser Diagnostics Raises $15.4M Through Private Placement Load More Breaking News New Products Posted to GenomeWeb: Qiagen, Thermo Fisher, Bionano Genomics, BillionToOne, More People in the News at Illumina Ventures, Element Biosciences, Epigenomics, Exagen, More Genomic Approaches Boost Rare Disease Diagnoses in Middle Eastern Patient Population GeneDx to Raise $150M in Public and Direct Stock Offerings In Brief This Week: T2 Biosystems, Novacyt, OpGen, Dante Genomics, Nautilus Biotechnology, More The Scan Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups. Genome-Wide Analysis Sheds Light on Genetics of ADHD A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder. MicroRNA Cotargeting Linked to Lupus A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus. Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.